Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸ : 2022-06-18±³À°ÀÏÀÚ : 2022-06-18
±³À°Àå¼Ò : ¿Â¶óÀÎ ¿¬¼ö±³À°(½Ç½Ã°£ È»ó °ÀÇ) ¹× ¼¿ï·Ôµ¥È£ÅÚ 2Ãþ 3°³·ë
±³À°ÁÖÁ¦ :
(¿Â∙¿ÀÇÁ¶óÀÎ º´Çà) Á¦48Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ ¹× Á¦2ȸ ¾Æ½Ã¾ÆÁ¾¾çÇÐȸ ±¹Á¦Çмú´ëȸÁÖÃÖ±â°ü : ´ëÇѾÏÇÐȸ
´ã´çÀÚ : ÀÌÈñ¿¬
¿¬¶ôó : 02-792-1486
À̸ÞÀÏ :
cancer2@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, ¼ºÇü¿Ü°ú, ¾È°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, ºñ´¢ÀÇÇаú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ÇغÎÇÐ, »ý¸®ÇÐ, »ýÈÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 200,000¿ø
ºñ°í 1. ȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 10¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 10¸¸¿ø 2. ºñȸ¿ø: 1) ±³¼ö, Àü¹®ÀÇ, ¼±ÀÓ¿¬±¸¿ø: 15¸¸¿ø / 2) Àü°øÀÇ, ¿¬±¸¿ø, ´ëÇпø»ý: 5¸¸¿ø / 3) ¾÷ü ¹× ¿¬±¸¼Ò: 20¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-18 Room A 08:40~09:10 Modifiers of cancer immunity Á¤ÁØÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-18 Room A 09:10~09:40 Novel discovery of antibody-drug conjugates for advanced cancers Kaku Saito(Daiichi Sankyo, Inc, USA)
±³À°½Ã°£ 06-18 Room A 09:40~10:10 PROTAC in cancer therapy ½Éź¸(¿¬¼¼ÀÇ´ë)
Åä·Ð 06-18 Room A 10:10~10:20 Q&A Discussion ()
±³À°½Ã°£ 06-18 Room B 08:40~09:05 Addressing cancer care disparities through collaboration: opportunities and future directions Winnie K.W.So(The Chinese University of Hong Kong, Hong Kong, China)
±³À°½Ã°£ 06-18 Room B 09:05~09:30 Care of cancer survivors in a multi-disciplinary center Janette Vardy(University of Sydney, Australia)
±³À°½Ã°£ 06-18 Room B 09:30~09:55 Networking development and information sharing among Asian oncology nurses ¼Àº¿µ(¼¿ï´ë °£È£´ë)
±³À°½Ã°£ 06-18 Room B 09:55~10:20 Integration of supportive palliative care through the overall trajectory of cancer care °í¼öÁø(¿ï»ê´ëÇб³º´¿ø)
ÈÞ½Ä 06-18 10:20~10:40 ÈÞ½Ä ()
±³À°½Ã°£ 06-18 Room A 10:40~11:05 Update of NTRK inhibitors for NTRK fusion-positive tumors David S. Hong(The University of Texas MD Anderson Cancer Center , USA)
±³À°½Ã°£ 06-18 Room A 11:05~11:30 Pembrolizumab for MSI-H or dMMR tumors ¿Àµµ¿¬(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-18 Room A 11:30~11:55 HER2 targeted agents in breast, gut, and beyond Á¤°æÇØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-18 Room A 11:55~12:20 Novel clinical trial designs for tissue-agnostic drug development ±èÁöÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-18 Room B 10:40~11:05 Endoscopic resection Á¤ÈÆ¿ë(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-18 Room B 11:05~11:30 Surgical resection Toshiro Nishida(National Cancer Center Hospital, Japan)
±³À°½Ã°£ 06-18 Room B 11:30~11:55 Chemotherapy Li-Tzong Chen(Kaohsiung Medical University, Taiwan)
±³À°½Ã°£ 06-18 Room B 11:55~12:20 Molecular pathology of GISTs for precision medicine ÀÌÇý½Â(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-18 Room C 10:40~11:05 Algorithm based approach for spinal metastasis Fon-Yih Tsuang(National Taiwan University Hospital, Taiwan)
±³À°½Ã°£ 06-18 Room C 11:05~11:30 Total en block spondylectomy and immunotherapy for spinal metastasis Kota Watanabe(Keio University School of Medicine, Japan)
±³À°½Ã°£ 06-18 Room C 11:30~11:55 Recent update of radiotherapy for spinal bone metastasis Arjun Sahgal(University of Toronto, Canada)
±³À°½Ã°£ 06-18 Room C 11:55~12:20 Role of chemotherapy for spinal bone metastasis ±èÅ¿ë(¼¿ï´ëº´¿ø)